The TACL study in children with relapsed ALL demonstrated that the combination of bortezomib with vincristine, dexamethasone, doxorubicin, and pegylated asparaginase is highly active in B-precursor ALL but not in T-ALL (47). The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.